Back to results
US 2016/0355544 A1Published application
Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis
AssigneeVirginia Commonwealth University
InventorShunlin Ren
Life of this patent
Estimating the term…
Abstract
5-cholesten, 3β, 25-diol, disulfate (25HCDS) has been found to be an authentic PPARγ agonist and LXR antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.
Claims20
A compound which is:
- (i) 5-cholesten, 3b, 25-diol, disulfate (25HCDS) of the formula
- or (ii) a pharmaceutically acceptable salt thereof;
- for use as a medicament.
Dependencies are inferred from the claim text.